Green Cross Essential Therapeutics LLC is categorized under Malaria Control in New York City, NY and active since 2004.
Green Cross Essential Therapeutics LLC was established in 2004, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Malaria Control business, which does work in the B2B market, and is classified as a Malaria Control, under code number 561710 by the NAICS.
If you are seeking more information, feel free to contact Myung Hi Sonserai Lee at the company’s single location by writing to Uknown, New York City, New York NY 10036 or by phoning (917) 680-2905. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Green Cross Essential Therapeutics LLC |
| Contact Person: | Myung Hi Sonserai Lee |
| Address: | Uknown, New York City, New York 10036 |
| Phone Number: | (917) 680-2905 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2004 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Malaria Control |
| SIC Code: | 4959 |
| NAICS Code: | 561710 |
| Share This Business: |
Green Cross Essential Therapeutics LLC was started in 2004 to provide professional Malaria Control under the SIC code 4959 and NAICS code 561710. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Myung Hi Sonserai Lee for inquiries that concern Green Cross Essential Therapeutics LLC by calling the company number (917) 680-2905, as your correspondence is most welcome. Additionally, the physical location of the single location of Green Cross Essential Therapeutics LLC can be found at the coordinates as well as the street address Uknown in New York City, New York 10036.
For its online presence, you may visit Green Cross Essential Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.